Predominantly hemorrhagic neovascular age-related macular degeneration (AMD) has a very poor natural history, lead- ing to severe visual loss. Patients and Methods Retrospective study of patients with predominantly hemorrhagic AMD treated with intravitreal ranibizumab at the Jules Gonin Eye Hospital between December 2006 and December 2008. Baseline and monthly follow- up exams included visual acuity (VA), fundus exam and optical coherence tomography while fluorescein and indocyanine green angiography were performed at least every three months. Results The study included 8 eyes. Mean follow-up was 13 months (SD: 6.3). The mean number of intravitreal injections administered for each patient was 6.4 (SD: 2). 63% of the patients demonstrated stable or improved VA. The size of hemorrhage at baseline was inversely correlated to the final VA (P: 0.038) and positively corre- lated to the final central macular thickness (P: 0.021). Anticoagula- tion treatment was inversely correlated to the time of hemorrhage resolution (P: 0.039). Conclusions Intravitreal ranibizumab should be considered as a therapeutic option for predominantly hemor- rhagic lesions due to neovascular AMD.